Langerhans cell histiocytosis (LCH) is a rare disorder in which abnormal cells of the myeloid immune-cell lineage accumulate in tissues and form inflammatory lesions. It is classified as an inflammatory myeloid neoplasm: the abnormal cells multiply clonally, while surrounding inflammation contributes substantially to tissue injury. LCH can affect almost any organ, especially bone, skin, lungs, and the pituitary region. Its course ranges from a solitary lesion that resolves to multisystem disease with life-threatening organ dysfunction.
Biological basis
The abnormal cells in LCH resemble Langerhans cells, specialized antigen-presenting cells normally found in the skin. Both express the proteins CD1a and langerin, also called CD207. However, LCH is not simply an overgrowth of normal skin Langerhans cells; evidence supports an origin in myeloid precursor cells at different stages of development.
Many lesions contain an acquired mutation that activates the MAPK–ERK signaling pathway, which regulates cell growth and survival. BRAF V600E is the most common individual alteration. Mutations involving MAP2K1 and other pathway components occur in additional cases.
These findings established LCH as a clonal neoplastic disorder rather than a purely reactive immune condition. Nevertheless, its behavior differs from that of many conventional forms of cancer: some localized lesions regress, whereas other forms persist, recur, or damage multiple organs. The cellular infiltrate typically includes eosinophils, lymphocytes, and other inflammatory cells alongside the neoplastic cells.
LCH is not contagious and is generally not inherited. The mutations found in lesions are usually acquired during life rather than transmitted through families.
Epidemiology and classification
LCH occurs at any age but is diagnosed more often in children, particularly young children. Childhood incidence is generally estimated at several cases per million children annually; adult estimates are less certain because recognition and reporting vary.
Clinical classification is based principally on the extent of disease:
- Single-system LCH: one organ or organ system is involved. This may be unifocal, such as one bone lesion, or multifocal, such as several bone lesions.
- Multisystem LCH: two or more organs or organ systems are involved.
- Multisystem LCH with risk-organ involvement: disease affects the liver, spleen, or hematopoietic system. Involvement of these organs is associated with a greater risk of death, particularly when initial treatment response is poor.
The lungs are important sites of disease but are not included in the current pediatric risk-organ category. Certain craniofacial bone lesions are associated with a higher risk of pituitary or neurological complications; this is distinct from the risk-organ classification used to assess mortality risk.
Clinical manifestations
Bone and skin
Bone involvement commonly affects the skull, jaw, vertebrae, ribs, pelvis, or long bones. Lesions destroy localized areas of bone and may produce pain, swelling, fractures, or loosening of teeth. Vertebral involvement can cause marked flattening of a vertebral body, known as vertebra plana.
Skin disease may appear as scaly patches, crusted papules, or lesions resembling seborrheic dermatitis. The scalp, skin folds, and diaper area are characteristic locations in infants. Petechial or purpuric lesions may also occur. Some infant skin lesions regress, but skin findings alone do not establish whether disease is confined to the skin.
Pituitary and nervous system
Involvement of the pituitary stalk or hypothalamus can cause central diabetes insipidus, also called arginine vasopressin deficiency. This produces excessive urination and thirst and is distinct from diabetes mellitus. Other pituitary hormone deficiencies may affect growth, thyroid function, puberty, or reproductive function.
Less commonly, LCH causes masses within the central nervous system or an associated neurodegenerative syndrome. Manifestations can include impaired coordination, speech changes, and cognitive or behavioral difficulties. Neurological complications may develop after other disease sites have become inactive.
Lungs and other organs
Pulmonary LCH in adults is strongly associated with cigarette smoking and often occurs without disease elsewhere. It can cause cough, breathlessness, lung nodules, and cysts. Complications include spontaneous pneumothorax and pulmonary hypertension.
Multisystem disease may produce enlarged lymph nodes, liver or spleen enlargement, anemia, low platelet counts, or other evidence of impaired blood-cell production. Liver involvement can cause bile-duct damage and progressive fibrosis, sometimes continuing despite control of active lesions.
Diagnosis
Definitive diagnosis usually requires a biopsy of an accessible lesion. On histopathological examination, characteristic cells have grooved or folded nuclei and are often accompanied by eosinophils. Expression of CD1a and langerin in an appropriate tissue and clinical context supports the diagnosis. S100 is commonly positive but is less specific.
Electron microscopy historically demonstrated Birbeck granules, distinctive intracellular structures associated with langerin. It is generally unnecessary when appropriate immunohistochemical testing is available.
Molecular testing can identify BRAF V600E or other pathway alterations. These results may inform treatment selection, but absence of a detectable mutation does not exclude LCH.
Assessment of disease extent combines clinical examination, laboratory tests, and imaging. Depending on the presentation, investigations may include:
- Blood counts and tests of liver function.
- Skeletal imaging and positron-emission tomography combined with CT.
- Magnetic resonance imaging for suspected pituitary, brain, spinal, or adjacent soft-tissue involvement.
- High-resolution computed tomography and lung-function testing for pulmonary disease.
The differential diagnosis includes infection, other inflammatory disorders, primary bone tumors, lymphoma, and other histiocytic neoplasms. Pulmonary LCH may sometimes be diagnosed without biopsy when the clinical setting and imaging pattern are sufficiently characteristic.
Treatment
Treatment depends on age, affected organs, organ function, molecular findings, and previous disease behavior. Pediatric and adult approaches overlap but are not identical.
A solitary bone lesion may resolve after diagnostic biopsy or limited curettage. Selected localized lesions are managed with observation or local treatment rather than systemic therapy. Extensive surgery is generally avoided when it would cause unnecessary functional or structural damage.
Multifocal or multisystem disease may require systemic treatment. Vinblastine with a corticosteroid is an established pediatric regimen. Cytarabine and cladribine are used in selected settings, including adult or recurrent disease. Regimen selection varies with disease characteristics and treatment protocols.
BRAF and MEK inhibitors are forms of targeted therapy used in selected patients, particularly those with severe, refractory, or recurrent disease. They can produce substantial responses, but recurrence after discontinuation is an important limitation. The optimal treatment duration and long-term effects remain areas of study.
Smoking cessation is a central component of care for smoking-associated pulmonary LCH. Persistent endocrine deficiencies may require hormone replacement even after active LCH has been controlled.
Prognosis and long-term effects
Prognosis varies substantially. Localized disease generally has excellent survival, whereas multisystem disease with risk-organ dysfunction carries greater risk. Response to initial treatment is an important prognostic indicator.
Reactivation can occur at previously affected or new sites. Long-term effects include permanent pituitary deficiencies, hearing impairment, skeletal abnormalities, chronic lung disease, liver damage, and neurological disability. Resolution of active lesions does not necessarily reverse established organ injury.
Follow-up therefore addresses both recurrent disease and delayed complications. Individuals with LCH also have an increased observed occurrence of other malignancies, although the contributions of shared biological factors, treatment exposure, and surveillance differ across settings.
Historical terminology
The name histiocytosis X was introduced in 1953 to group conditions previously described as eosinophilic granuloma, Hand–Schüller–Christian disease, and Letterer–Siwe disease. These historical labels described different clinical patterns rather than separate diseases with distinct cellular origins.
The modern name reflects recognition of the lesional cells’ resemblance to Langerhans cells. Contemporary classification emphasizes organ distribution, risk-organ involvement, and molecular biology rather than the older eponymous categories.